OSAKA -- Japan's Nitto Denko has acquired two U.S. biomedical companies so it can handle all drug production steps on its own.
The roughly 5 billion yen ($48.3 million) in total outlays shows the Osaka-based company's increasing focus on the medical segment amid weakness in its mainstay electronics materials business.
